AstraZeneca's NIAGARA Phase 3 Trial Of Imfinzi (Durvalumab) Plus Chemotherapy Showed Statistically Significant And Clinically Meaningful Improvement In Event-free Survival And Overall Survival Vs Neoadjuvant Chemotherapy In Muscle-invasive Bladder Cancer
AstraZeneca's NIAGARA Phase 3 Trial Of Imfinzi (Durvalumab) Plus Chemotherapy Showed Statistically Significant And Clinically Meaningful Improvement In Event-free Survival And Overall Survival Vs Neoadjuvant Chemotherapy In Muscle-invasive Bladder Cancer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.